lu af35700

Lu AF35700 is an investigational oral antipsychotic developed by Lundbeck for the treatment of schizophrenia and schizoaffective disorder, particularly targeting treatment-resistant cases. It acts as a modulator of dopaminergic and serotonergic systems, specifically functioning as a dopamine D1 receptor modulator with relatively lower D2 receptor occupancy, and exhibits high occupancy at serotonin 5-HT2A and 5-HT6 receptors. This pharmacological profile was designed to provide antipsychotic efficacy while minimizing adverse effects commonly associated with higher D2 antagonism, such as extrapyramidal symptoms and prolactin elevation. Despite initial promise—including FDA Fast Track designation—clinical trials failed to show significant benefit over conventional antipsychotics in treatment-resistant schizophrenia. Development for both schizophrenia and schizoaffective disorder has been discontinued[1][2][3][5][6].